Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Subramaniam Shymalagovindarajan"'
Autor:
Kiran Mahajan, Ernst Schonbrunn, Nicholas J. Lawrence, Ranjan Perera, Youngchul Kim, Uwe Rix, Subramaniam Shymalagovindarajan, Jingsong Zhang, Jasreman Dhillon, Domenico Coppola, Anthony M. Magliocco, John Puskas, Norbert Berndt, Rezaul M. Karim, Steven Gunawan, Yunyun Chen, Neha Agarwal, Brent M. Kuenzi, Muhammad Ayaz, Harshani R. Lawrence, Alexey M. Eroshkin, Ami K. Patel, Duy T. Nguyen, Jiqiang Yao, Niveditha Nerlakanti
Supplementary Table 1: Table provides information on the siRNA sequences and/or chemical structures of the non-FDA approved inhibitors for bromodomain proteins, transcription factors and kinases described in the current study. Supplementary Table 2:
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ce2b2dd01ae32a0980a741719a0d9f3
https://doi.org/10.1158/1535-7163.22504902.v1
https://doi.org/10.1158/1535-7163.22504902.v1
Autor:
Kiran Mahajan, Ernst Schonbrunn, Nicholas J. Lawrence, Ranjan Perera, Youngchul Kim, Uwe Rix, Subramaniam Shymalagovindarajan, Jingsong Zhang, Jasreman Dhillon, Domenico Coppola, Anthony M. Magliocco, John Puskas, Norbert Berndt, Rezaul M. Karim, Steven Gunawan, Yunyun Chen, Neha Agarwal, Brent M. Kuenzi, Muhammad Ayaz, Harshani R. Lawrence, Alexey M. Eroshkin, Ami K. Patel, Duy T. Nguyen, Jiqiang Yao, Niveditha Nerlakanti
Supplementary Fig. 1. Epigenetic landscape and the transcription cofactor recruitment at the HOXB13 enhancer region under various treatments; Supplementary Figure 2. BRD4 is a target of the dual BET-kinase inhibitors in CRPCs; Supplementary Figure 3.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba9532fee211fdd48d8b5145a41ce0a4
https://doi.org/10.1158/1535-7163.22504905.v1
https://doi.org/10.1158/1535-7163.22504905.v1
Autor:
Youngchul Kim, Kiran Mahajan, Jasreman Dhillon, Jingsong Zhang, Steven Gunawan, Norbert Berndt, Domenico Coppola, Neha Agarwal, Rezaul M. Karim, Niveditha Nerlakanti, Alexey Eroshkin, Ernst Schönbrunn, Brent M. Kuenzi, Duy T. Nguyen, John Puskas, Yunyun Chen, Anthony M. Magliocco, Muhammad Ayaz, Jiqiang Yao, Nicholas J. Lawrence, Harshani R. Lawrence, Uwe Rix, Ami Patel, Ranjan J. Perera, Subramaniam Shymalagovindarajan
Publikováno v:
Molecular Cancer Therapeutics. 17:2796-2810
Resistance to androgen receptor (AR) antagonists is a significant problem in the treatment of castration-resistant prostate cancers (CRPC). Identification of the mechanisms by which CRPCs evade androgen deprivation therapies (ADT) is critical to deve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b768533c84684ddbb5d69426258c0845
https://doi.org/10.1158/1535-7163.mct-18-0602
https://doi.org/10.1158/1535-7163.mct-18-0602
